According to Medicis Pharmaceutical, the FDA’s waiver provisions for the generic versions of the company’s once-daily oral acne drug, Solodyn (minocycline HCl), will put patients at risk. The company is asking the FDA to approve Solodyn’s generic versions only after in vivo bioequivalence testing for drug strength.